Your Thyroid Problem Is Actually A Conversion Problem

Your thyroid makes mostly T4, which is not the hormone your cells actually use. T4 is a storage form, a raw material that has to be converted into something called T3, which is the active hormone that controls your metabolism, your energy production, your mood, and your body temperature. When doctors talk about a thyroid problem, most people imagine the gland itself is broken. But in a large percentage of cases, the gland is doing exactly what it is supposed to do. The problem is what happens to the hormone after it leaves the thyroid.

That conversion step, from T4 to T3, happens outside the thyroid entirely. Somewhere between 70 and 90 percent of your active T3 is produced in peripheral tissue, meaning your liver, your kidneys, and your skeletal muscle. The thyroid is the factory, but the workers are everywhere else in your body.

The conversion is done by enzymes called deiodinases, which work by physically removing an iodine atom from T4 to produce T3. There are two main types relevant here. Type 1 deiodinase, which is concentrated in the liver and kidneys, handles most of the baseline T3 production circulating in your blood. Type 2 deiodinase is found in skeletal muscle and brain tissue and produces T3 locally, meaning the muscle itself gets a supply of active hormone made right where it is needed.

This is where muscle mass becomes quietly important. More skeletal muscle means more sites running type 2 deiodinase, which means more capacity to convert T4 into usable T3. The relationship runs the other direction too. T3 is part of what signals muscle cells to stay metabolically active, so when conversion is poor, you get less T3, which leads to less metabolic activity in muscle, which can reduce your conversion capacity further. The cycle feeds itself.

Now here is where the standard medical approach tends to fall short. The current guidelines from major thyroid organizations recommend using TSH, something called thyroid stimulating hormone, as the primary tool for diagnosing and monitoring thyroid function. TSH is a signal released from the pituitary gland in your brain that tells your thyroid to make more hormone. The logic is that if TSH is normal, the system is working. But TSH tells you what the pituitary is seeing. It does not tell you what is actually getting converted downstream.

A 2011 study in PLOS ONE looked at patients who had their thyroid removed entirely and were being treated with levothyroxine, which is synthetic T4. More than 20 percent of them had abnormal free T3 or free T4 levels even though their TSH was completely normal. These were patients whose TSH looked fine on paper but whose cells were not getting adequate active hormone. The pituitary was satisfied. The body was not.

The critique of the TSH only model is not new, though it has remained mostly outside mainstream clinical practice. A 2025 review in Frontiers in Endocrinology, written as a single author opinion piece rather than a systematic review, argued that the field has been working from a diagnostic framework built in the 1970s and has not fully accounted for how conversion efficiency varies between individuals. The argument is that two people with identical TSH can have meaningfully different T3 availability at the tissue level.

So what breaks conversion? Several things, and they are all things that respond to lifestyle before they respond to medication.

Low protein intake is one of them. Deiodinase enzymes require adequate substrate and cofactors to function, and chronic undereating of protein limits the raw material the liver and kidneys need to run the conversion process efficiently. A 2025 case report in Cureus documented a Hashimoto's patient whose thyroid antibodies and symptoms improved substantially on a structured high protein dietary intervention without any change to her medication. A case report is not a clinical trial, and it cannot establish causation, but it is consistent with the mechanism.

Selenium is another. The deiodinase enzymes are selenoproteins, meaning selenium is literally embedded in their structure and they cannot function without it. When selenium intake is chronically low, conversion slows at the enzymatic level.

Cortisol is a third, and probably the most common. Chronic stress drives elevated cortisol, and elevated cortisol shifts the conversion of T4 away from active T3 and toward something called reverse T3, which is an inactive form that can actually compete with T3 for receptor binding. Your body is making the hormone but blocking its own signal. This is sometimes called functional hypothyroidism because the labs can look passable while the person feels genuinely hypothyroid.

Exercise closes this loop in a few directions at once. A 2025 cross-sectional study in Biomolecules found that recreational exercise was associated with reduced inflammatory markers in patients with Hashimoto's thyroiditis, including lower levels of antibodies that attack thyroid tissue. Inflammation and immune activation are independent stressors that can impair conversion, so bringing them down through training is not just a vague wellness benefit. It is directly relevant to how well the system runs.

The practical hierarchy looks like this. Fix protein intake. Address selenium either through diet or supplementation. Manage chronic stress directly, because no amount of levothyroxine overcomes a cortisol environment that is rerouting T4 toward reverse T3. Build and maintain muscle, which preserves your peripheral conversion sites. Sleep, because cortisol regulation runs through sleep. Get a full panel including free T3, free T4, reverse T3, and TSH, not just TSH alone, so you actually know where in the chain the problem is.

If you do all of that and symptoms persist, there is clinical evidence that adding direct T3, called liothyronine, can move the needle in a way that T4 alone does not. A 2022 study in Frontiers in Endocrinology found that adding T3 to levothyroxine therapy improved quality of life in female hypothyroid patients who still had residual symptoms despite normal TSH on T4 alone. The conversion problem was bypassed by supplying the active hormone directly.

Most thyroid treatment is still built around replacing T4 and trusting the system to do the rest. But whether the system can do the rest depends entirely on what you are giving it to work with.

---

References

1. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. (2011). Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE 6(8):e22552. PMC3148220.
2. Cited for: the >20% of patients with abnormal FT3 or FT4 despite normal TSH on levothyroxine.
3. Limbaugh SL, Ennessy LA, Davis KS, Allen VT. (2025). Nutrition Based, High Protein Adjunct Therapy for Hashimoto's Thyroiditis: A Case Report. Cureus 17(9):e91597. PMC12495900.
4. Cited for: protein protocol resolving Hashimoto's symptoms.
5. Vuletić M, Žnidar V, Barić Žižić A, et al. (2025). Recreational Exercise and Inflammatory Patterns in Hashimoto's Thyroiditis: Observations from a Cross Sectional Study. Biomolecules 15(11):1510. PMC12650045.
6. Cited for: exercise reducing inflammatory markers in Hashimoto's patients.
7. Bjerkreim BA, Hammerstad SS, Gulseth HL, et al. (2022). Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy. Frontiers in Endocrinology 13:816566. PMC8902821.
8. Cited for: clinical evidence that adding T3 improves quality of life in patients with residual symptoms.
9. Lindner HH. (2025). Clinical thyroidology: beyond the 1970s' TSH T4 Paradigm. Frontiers in Endocrinology 16:1529791. PMC12234311.
10. Cited for: critique of the TSH only diagnostic model. Note: single author opinion piece.
11. European Thyroid Journal. Role of hepatic deiodinases in thyroid hormone homeostasis. PMC10160546.
12. Cited for: D1 distribution in liver and kidney, D2 distribution in skeletal muscle.
13. ScienceDirect Topics. Thyroxine Deiodinase.
14. Cited for: the 70-90 percent peripheral conversion figure.
15. Pituitary Foundation. Hormone Replacement Medication Interactions.
16. Cited for: thyroid hormone status affecting IGF-1 levels.
17. American Thyroid Association Guidelines on Treatment of Hypothyroidism.
18. Cited for: current guideline recommending TSH for monitoring without routine FT3 or rT3 testing.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness